KOSDAQ:A307750 Stock Report

Market Cap: ₩264.0b

KUKJEON PHARMACEUTICAL Past Earnings Performance

Past criteria checks 0/6

KUKJEON PHARMACEUTICAL's earnings have been declining at an average annual rate of -88.9%, while the Pharmaceuticals industry saw earnings growing at 10.1% annually. Revenues have been growing at an average rate of 17.4% per year. KUKJEON PHARMACEUTICAL's return on equity is 1%, and it has net margins of 1%.

Key information


Earnings growth rate


EPS growth rate

Pharmaceuticals Industry Growth11.3%
Revenue growth rate17.4%
Return on equity1.0%
Net Margin1.0%
Last Earnings Update31 Mar 2024

Recent past performance updates

KUKJEON PHARMACEUTICAL's (KOSDAQ:307750) Problems Go Beyond Poor Profit

Mar 27
KUKJEON PHARMACEUTICAL's (KOSDAQ:307750) Problems Go Beyond Poor Profit

Recent updates

KUKJEON PHARMACEUTICAL's (KOSDAQ:307750) Problems Go Beyond Poor Profit

Mar 27
KUKJEON PHARMACEUTICAL's (KOSDAQ:307750) Problems Go Beyond Poor Profit

Revenue & Expenses Breakdown

How KUKJEON PHARMACEUTICAL makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSDAQ:A307750 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 24129,4291,35113,5844,630
31 Dec 23121,9984,82412,8074,821
30 Sep 23116,6859,49612,8644,699
30 Jun 23113,9059,38912,3464,472
31 Mar 23110,27412,21212,0494,370
31 Dec 22103,7118,94811,4693,981
30 Sep 22102,7311,60310,8073,955
30 Jun 2297,0943,6749,7023,764
31 Mar 2292,5284,2559,1873,456
31 Dec 2185,3544,0388,8382,651

Quality Earnings: A307750 has a high level of non-cash earnings.

Growing Profit Margin: A307750's current net profit margins (1%) are lower than last year (11.1%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if A307750's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: A307750's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: A307750 had negative earnings growth (-88.9%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (18.9%).

Return on Equity

High ROE: A307750's Return on Equity (1%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.